Diary - News
All news Tollys earns award from MATWIN for its drug candidate TL-532
Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase.
Lyon, France, May 18, 2021 — Tollys, a biopharmaceutical company responsible for developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like receptor 3 (TLR3) specific agonist, today announces that it has been awarded the ‘Best-inClass Therapeutic Innovation’ prize by the MATWIN international board.
